Center for Thoracic Cancers, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Br J Cancer. 2021 May;124(11):1757-1758. doi: 10.1038/s41416-021-01344-7. Epub 2021 Mar 23.
Two RET inhibitors, selpercatinib and pralsetinib, recently received approval for the treatment of advanced RET fusion-positive lung cancer. Acquired resistance to these inhibitors will be a major challenge. We have shown that resistance can emerge due to recurrent RET kinase domain mutations and, in most cases, due to RET-independent mechanisms.
两种 RET 抑制剂，塞尔帕替尼和普拉替尼，最近被批准用于治疗晚期 RET 融合阳性肺癌。对这些抑制剂的获得性耐药将是一个主要挑战。我们已经表明，耐药性可能由于 RET 激酶结构域的反复突变以及在大多数情况下由于 RET 非依赖性机制而出现。
